A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 [panobinostat] when administered in combination with oral lenalidomide and dexamethasone in adult patients with multiple myeloma.

Trial Profile

A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 [panobinostat] when administered in combination with oral lenalidomide and dexamethasone in adult patients with multiple myeloma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Panobinostat (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 10 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
    • 10 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
    • 02 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top